Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06000501 · ClinicalTrials.gov registry record · Phase 4
Duration and Efficacy of Azstarys on Adult ADHD Symptoms and Executive Function in Early Evening
A Phase 4 study, sponsored by NYU Langone Health.
- Completed
- Registry status
- Phase 4
- Development phase
- 29
- Enrollment target
NCT06000501 is a Phase 4 study that has completed, run by NYU Langone Health. The registered enrollment target is 29 participants.
The verdict
NCT06000501, a Phase 4 study, has completed, sponsored by NYU Langone Health.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 29 participants
- Enrollment target
Study Summary
This is a single-site study. One purpose of this trial is to extend the safety and efficacy evidence basis for Azstarys in adults with ADHD. This open-label, treatment study will examine the efficacy of Azstarys on ADHD symptoms using the AISRS 18-item total score on the AISRS-expanded; the Adult ADHD Investigator Symptom Rating Scale. The investigators will also examine Executive Function later in the day (early evening, about 12 hours after first morning dosing).
Interventions
- DRUG Serdexmethylphenidate/dexmethylphenidate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2023-11-13 |
| Est. Completion | 2024-07-17 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06000501
The ClinicalTrials.gov registry entry for NCT06000501 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 29 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NYU Langone Health, which has 1,164 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Serdexmethylphenidate/dexmethylphenidate is the first listed.
NCT06000501 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06000501 about?
NCT06000501 is a clinical study titled "Duration and Efficacy of Azstarys on Adult ADHD Symptoms and Executive Function in Early Evening". This is a single-site study. One purpose of this trial is to extend the safety and efficacy evidence basis for Azstarys in adults with ADHD. This open-label, treatment study will examine the efficacy of Azstarys on ADHD symptoms using the AISRS 18-item total score on the AISRS-expanded; the Adult AD...
What is the current status of trial NCT06000501?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 29 participants. The study started on 2023-11-13. Estimated completion is 2024-07-17.
What interventions are being tested in trial NCT06000501?
The interventions under investigation include: Serdexmethylphenidate/dexmethylphenidate (DRUG).
Who is sponsoring clinical trial NCT06000501?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.